# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Johnson & Johnson unveils promising TARIS platform data for bladder cancer treatment, highlighting ease of administration a...
2024 Financial GuidanceGiven the proposed acquisition of Shockwave Medical by Johnson & Johnson (NYSE:JNJ), Shockwave Medic...
Johnson & Johnson's results in treating bladder and prostate cancer. Learn about TAR-210's efficacy in high-risk NM...
Updated results reinforce the potential of TAR-210 to transform treatment of non–muscle-invasive bladder cancer with fibroblast...
Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price...
Study highlights opportunity for treatment intensification in this population since approximately 50% of patients with high-ris...
- Reuters
U.S. stocks look to push ahead on a positive path, now that the Federal Reserve’s rate decision is in the rearview mirror. Majo...